{"id":391559,"date":"2014-09-12T00:00:00","date_gmt":"2014-09-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforus1214-biopharma-physician-crohns-disease-and-ulcerative-colitis-u-s-physician-and-payer-perspectives-on\/"},"modified":"2026-03-31T09:04:43","modified_gmt":"2026-03-31T09:04:43","slug":"pforus1214-biopharma-physician-crohns-disease-and-ulcerative-colitis-u-s-physician-and-payer-perspectives-on","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforus1214-biopharma-physician-crohns-disease-and-ulcerative-colitis-u-s-physician-and-payer-perspectives-on\/","title":{"rendered":"Physician &#038;Crohn\u2019s Disease and Ulcerative Colitis: U.S. Physician and Payer Perspectives on Established and Recently Launched Biologics, Emerging Novel Agents and Biosimilars | Payer Forum | US | 2014"},"content":{"rendered":"<p>Crohn\u2019s disease (CD) and ulcerative colitis (UC) are two gastrointestinal autoimmune\/inflammatory indications that commonly feature treatment with biological therapies. The U.S. CD market consists of five approved biologics, and the UC market consists of four; the most recent agent\u2014Takeda\u2019s Entyvio (vedolizumab; CD and UC)\u2014received FDA approval in May 2014. In both CD and UC, Janssen\u2019s Remicade (infliximab) continues to lead the U.S. market in sales and patient share as the therapy to beat for agents targeting patients refractory to conventional, less-costly agents, followed by AbbVie\u2019s Humira (adalimumab). Despite the positive impact of these TNF-\u03b1 inhibitors on CD and UC treatment, U.S. gastroenterologists indicate that novel agents are still needed that offer the basic clinical attributes of inducing and maintaining clinical remission at higher rates. With the recent launch of Entyvio and the anticipated launches of Janssen\u2019s Stelara (ustekinumab) for CD and Pfizer\u2019s Xeljanz (tofacitinib) for UC in the near future, the competitive environment will intensify, presenting physicians with additional therapy options for moderate-to-severe disease.<\/p>\n<p>In this report, we gauge physicians\u2019 and payers\u2019 opinions of current biologics and emerging therapies for CD and UC to anticipate potential changes in the prescribing patterns and reimbursement climate. We focus on the available TNF-\u03b1 inhibitors Remicade, Humira, Janssen\u2019s Simponi (golimumab), and UCB\u2019s Cimzia (certolizumab pegol); the cell adhesion molecule inhibitors Biogen Idec\u2019s Tysabri (natalizumab) and Entyvio; and the emerging therapies Stelara and Xeljanz. In addition, we discuss physicians\u2019 and payers\u2019 opinions of biosimilars for infliximab and adalimumab, which we anticipate will launch during the same time frame as the branded agents, and how they will affect potential patient share of currently available and emerging therapies.<\/p>\n","protected":false},"template":"","class_list":["post-391559","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-therapy-areas-ulcerative-colitis","biopharma-product-biosimilars","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391559","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391559\/revisions"}],"predecessor-version":[{"id":577008,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391559\/revisions\/577008"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391559"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}